abstract |
Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R1, R2 , R3 and R4 have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis. |